Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04002583
Other study ID # 19-003078
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 19, 2020
Est. completion date December 2025

Study information

Verified date March 2024
Source Mayo Clinic
Contact Sabrina Bunn
Phone 904-953-3930
Email bunn.sabrina@mayo.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Researchers are trying to determine the frequency of seizures and epilepsy in patients with Early-onset Alzheimer's disease (EOAD) using a 48-hour computer assisted ambulatory electroencephalogram.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 40 Years to 64 Years
Eligibility Inclusion criteria for EOAD patients will be recruited from the LEADS trial with the following: - 40 to 64 years of age - Meets NIA-AA criteria for mild cognitive impairment (MCI) due to AD or probable AD dementia. - Have a global CDR score of = 1.0 - Have capacity to provide informed consent (ICF) or has a legal authorized representative or guardian who provides IC. - Amyloid positive status (PET scan with evidence of elevated amyloid) - Must have a study partner (informant) who spends a minimum average of 10 hours per week with the participant (e.g., family member, significant other, friend, and caregiver) who is generally aware of the participants' daily activities and can provide information about the participant's cognitive and functional performance. If the participant does not have a study partner who spends 10 face-to-face hours per week, other arrangements for identifying a viable study partner will be granted on a case-by-case basis by the Site PI. - Not pregnant or lactating. Women must be two years post-menopausal, be surgically sterile, or have a negative pregnancy test prior to each PET scan - Fluent in English. Exclusion Criteria: - Meets core clinical criteria for non-AD dementia. - Two or more first degree relatives with a history of EOAD suggestive of autosomal dominant transmission, unless known pathogenic mutations in APP, PSEN1, PSEN2 have been excluded. - Known mutation in an ADAD gene (APP, PSEN1, PSEN2) or other autosomal dominant genes associated with other neurodegenerative disorders. - MRI scans with evidence of infection or focal lesions, cortical strokes, multiple lacunes (single lacune is allowable unless it meets criteria for strategic lacune affecting cognition) - Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol (at the discretion of the Site PI) - Medical history of a brain disorder other than the disorder causing dementia except for headache. - Deemed ineligible by the Site PI for any other reason.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Computer assisted ambulatory electroencephalogram
A portable 16 channel CAA-EEG is used to detect epileptiform abnormalities in a 48 hour ambulatory electroencephalogram (EEG)

Locations

Country Name City State
United States Mayo Clinic in Florida Jacksonville Florida

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Electrographic seizures: Number of subjects with electrographic seizures Number of subjects with electrographic seizures in 48 hours on computer assisted ambulatory EEG 48 hours
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03634007 - Gene Therapy for APOE4 Homozygote of Alzheimer's Disease Phase 1/Phase 2
Completed NCT00867828 - Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE) Phase 4
Completed NCT03923517 - RHAPSODY-plus: Online Counseling for Family Caregivers of Patients With Young Onset Dementia N/A
Terminated NCT01400542 - Sleep Apnea in Early to Mid-Stage Alzheimer's Disease N/A
Recruiting NCT02875496 - Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain
Recruiting NCT03507257 - Longitudinal Early-onset Alzheimer's Disease Study Protocol